This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n9http://localhost/temp/predkladatel/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F14%3A10286356%21RIV15-MSM-11110___/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F14%3A10286356%21RIV15-MSM-11110___
rdf:type
skos:Concept n13:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1038/tpj.2014.3
dcterms:description
Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P < 1 x 10(-5)): three contain genes of particular biological interest (ZMIZ1, TGIF1 and CFTR). These data suggest a role for novel pathways in MTX response and further investigations within associated regions will help to reach our goal of predicting response to MTX in JIA. Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P < 1 x 10(-5)): three contain genes of particular biological interest (ZMIZ1, TGIF1 and CFTR). These data suggest a role for novel pathways in MTX response and further investigations within associated regions will help to reach our goal of predicting response to MTX in JIA.
dcterms:title
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases
skos:prefLabel
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases
skos:notation
RIV/00216208:11110/14:10286356!RIV15-MSM-11110___
n4:aktivita
n17:S
n4:aktivity
S
n4:cisloPeriodika
4
n4:dodaniDat
n18:2015
n4:domaciTvurceVysledku
n7:6199380
n4:druhVysledku
n11:J
n4:duvernostUdaju
n19:S
n4:entitaPredkladatele
n14:predkladatel
n4:idSjednocenehoVysledku
18146
n4:idVysledku
RIV/00216208:11110/14:10286356
n4:jazykVysledku
n12:eng
n4:klicovaSlova
cases; arthritis; idiopathic; juvenile; cohort; large; response; methotrexate; for; genes; novel; reveal; data; Genome-wide
n4:klicoveSlovo
n6:large n6:data n6:novel n6:juvenile n6:cohort n6:reveal n6:response n6:genes n6:for n6:idiopathic n6:methotrexate n6:arthritis n6:Genome-wide n6:cases
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[3DB29D255AFE]
n4:nazevZdroje
Pharmacogenomics Journal
n4:obor
n16:FG
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
21
n4:rokUplatneniVysledku
n18:2014
n4:svazekPeriodika
14
n4:tvurceVysledku
Ursu, S. Bohm, M. Cobb, J. van Zeist, B. Flynn, E. Moncrieffe, H. Kassoumeri, L. de Jonge, R. Wulffraat, N. Hinks, A. Patrick, F. Doležalová, Pavla Bulatovič, M. Cule, E.
n4:wos
000340216000008
s:issn
1470-269X
s:numberOfPages
14
n15:doi
10.1038/tpj.2014.3
n9:organizacniJednotka
11110